These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466 [TBL] [Abstract][Full Text] [Related]
9. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting. Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635 [TBL] [Abstract][Full Text] [Related]
10. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ; N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304 [TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial. Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748 [TBL] [Abstract][Full Text] [Related]
12. Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. Rabbani LE; Iyengar S; Dangas GD; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Stant J; Fahy M; Lansky AJ; Mehran R; Stone GW J Interv Cardiol; 2009 Aug; 22(4):378-84. PubMed ID: 19496901 [TBL] [Abstract][Full Text] [Related]
13. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. Jeremias A; Vasu S; Gruberg L; Kastrati A; Stone GW; Brown DL Catheter Cardiovasc Interv; 2010 May; 75(6):895-902. PubMed ID: 20088008 [TBL] [Abstract][Full Text] [Related]
14. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW; Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213 [TBL] [Abstract][Full Text] [Related]
15. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). Dangas G; Aymong ED; Mehran R; Tcheng JE; Grines CL; Cox DA; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Lansky AJ; Stone GW; Am J Cardiol; 2004 Oct; 94(8):983-8. PubMed ID: 15476608 [TBL] [Abstract][Full Text] [Related]